MétaCan
Menu
Back to cohort

Clinical outcome and biological predictors of relapse following nephrectomy only for very low risk Wilms tumor (VLR WT): A report from Children’s Oncology Group AREN0532.

2015· article· en· W2623294256 on OpenAlexaff
Conrad V. Fernandez, Elizabeth J. Perlman, Elizabeth A. Mullen, Yueh‐Yun Chi, Thomas E. Hamilton, Kenneth W. Gow, Fernando Ferrer, Douglas C. Barnhart, Peter F. Ehrlich, Geetika Khanna, John A. Kalapurakal, Tina Bocking, Vicki Huff, Qi An, James I. Geller, Paul E. Grundy, Jeffrey S. Dome, Robert C. Shamberger

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicRenal and related cancers
Canadian institutionsAlberta HealthIzaak Walton Killam Health Centre
Fundersnot available
KeywordsMedicineNephrectomyInternal medicineWilms' tumorHazard ratioLoss of heterozygosityStage (stratigraphy)OncologyHistologyGastroenterologyPathologySurgeryKidneyAlleleConfidence interval

Abstract

fetched live from OpenAlex

10023 Background: An earlier study of observation only following nephrectomy for VLR WT defined as stage I, age < 2 years, favorable histology with a weight<550 grams was suspended for excess relapse. Follow up revealed a higher salvage rate than originally predicted and suggested novel prognostic biomarkers. In this study, we sought to determine if 1) an observation alone strategy in centrally reviewed VLR WT demonstrates an Event Free Survival (EFS) of > 85% and Overall Survival (OS) of > 95%, and 2) to validate prognostic biomarkers. Methods: From 10/30/2006-8/12/2013, 116 eligible patients were enrolled with VLR WT; negative lymph node sampling was required and predisposition syndromes were excluded. All cases had central review of pathology, diagnostic imaging and surgical reports on the AREN03B2 biology and classification study. Evaluable tumors were analyzed for mutation of WT1, 1p and 16q loss of heterozygosity (LOH) using microsatellite analysis, 1q gain, 1p and 16q loss by MLPA, and 11p15 loss or retention of imprinting (LOI, ROI) using methylation restriction sites analysis. Results: Median follow up was 80 months (5-97). Median age was 11.5 months (0.1-23). 12 patients relapsed with no deaths. Estimated 4-year EFS was 89.7% (95% CI 84.1-95.2%) and OS was 100%. 1 patient is alive with disease after 4 relapses. First site of relapse was lung (n=5), tumor bed (n=4), abdomen (n=2), contralateral kidney (n=1). Median time to first relapse was 4.2 months (2.2-43). The presence of intralobar (p=0.46) or perilobar rests (p=1.0) was not associated with relapse, nor was histological subtype (p=0.16). 1q gain, 1p loss and/or 16q loss did not predict relapse, nor did WT1 mutation (but 13/14 with WT1 mutations also had 11p15 LOH). 11p15 methylation status predicted relapse. Conclusions: Most patients meeting VLR criteria can be safely managed by nephrectomy alone. 11p15 LOH/LOI predicts relapse. Future trials considering expansion of an observation alone strategy for low risk WT should incorporate these biomarkers. Clinical trial information: NCT00352534. Relapse No Relapse Yes Total P value 11p15 LOH 32 (80%) 8 (20%) 40 0.0106 11p15 ROI 58 (97%) 2 (3%) 60 11p15 LOI 6 (75%) 2 (25%) 8 Total 96 (89%) 12 (11%) 108

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.064
GPT teacher head0.410
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicRenal and related cancersFrench-language works237,207